BrachyDOSE Funding Secures €554K to Advance Radiation Safety in Cancer Treatment

Lithuania-based medtech startup BrachyDOSE has raised €554,000 in new funding to clinically test its data-driven radiation measurement technology, aimed at significantly improving safety and outcomes in radiotherapy. The investment round was led by Coinvest Capital and joined by BSV Ventures, along with Lithuanian and Estonian angel networks LitBAN and EstBAN.

The company’s proprietary system combines hardware sensors and a software platform that leverages an injury prediction algorithm to guide clinical decisions during cancer treatments. This dual approach offers real-time dose measurement during radiotherapy, allowing doctors to prevent treatment-related injuries and tailor therapies more precisely.

BrachyDOSE has already collaborated with major national cancer centers in Lithuania, including Vilnius University Hospital Santaros Clinics and the Lithuanian University of Health Sciences Oncology Hospital. The company is preparing for CE and MDR certification, essential regulatory steps before commercial rollout in both Lithuanian and international markets.

Founded and led by Neringa Šeperienė, who holds advanced degrees in applied and medical physics and a PhD in materials engineering from Kaunas University of Technology, BrachyDOSE is built by a multidisciplinary team. It includes experts in medical device engineering, data analytics, medical physics, and oncology.

The startup’s technology addresses a major gap in cancer care: until now, radiation dose estimates have relied on approximations. With real-time feedback, BrachyDOSE enables greater accuracy in dose delivery, reducing unintended side effects and enhancing patient recovery.

Investor Sandra Golbreich of BSV Ventures highlighted the impact of this precision. Radiotherapy is a foundational treatment for many cancers, yet many hospitals lack exact tools to monitor dosage on a patient-by-patient basis. BrachyDOSE brings a much-needed solution to this challenge, improving the quality and safety of care globally.

According to Coinvest Capital’s managing director Viktorija Trimbel, the success of this round is not only a testament to BrachyDOSE’s potential but also a significant step forward for Lithuania’s medtech innovation sector. With modern infrastructure and decades of oncology expertise, the country is well-positioned to become a leader in exporting advanced cancer care technologies.

A portion of the raised funds will go toward expanding the team, including hiring a medical device salesperson, as BrachyDOSE prepares for broader market entry.

Once certified, the solution will be offered to hospitals worldwide, making radiotherapy safer, more efficient, and cost-effective, and enabling faster patient recovery.